The New England Journal of Medicine last week released a study showing that the use of dexamethasone resulted in a lower, 28-day mortality rate among patients receiving invasive ventilation or oxygen.

The study indicated lower incidence of death among 2,104 patients treated with dexamethasone, compared to 4,321 patients receiving usual care. However, results showed very little impact in patients not receiving respiratory support.

The Food and Drug Administration also recently updated its COVID-19 treatment guidelines for corticosteroids, including dexamethasone. FDA said such drugs can be used for up to 10 days in patients requiring supplemental oxygen, but not with those who are mechanically ventilated or do not require supplemental oxygen.

Related News Articles

Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is holding an emergency meeting this afternoon on the Johnson…
Headline
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2…
Headline
The Food and Drug Administration and Centers for Disease Control and Prevention today jointly recommended a pause in the use of Johnson & Johnson’s…
Blog
Our doctors, nurses and clinical staff have responded to the COVID-19 pandemic with dedication and bravery. Yet, the pandemic’s longevity, as well as COVID-19’…
Headline
The Centers for Medicare & Medicaid Services will no longer waive certain requirements for long-term care and skilled nursing facilities beginning May 9 or…
Chairperson's File
One legacy of our response to COVID-19 surely will be how it has accelerated the adoption of virtual care. It is one of the more encouraging developments…